P Wang1,2, H-M Li1,2, Y-F Zou1,2, J-H Tao3, H-F Pan4,5. 1. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, 230032, Hefei, Anhui, China. 2. Anhui Provincial Laboratory of Population Health & Major Disease Screening and Diagnosis, Hefei, Anhui, China. 3. Department of Rheumatology, Anhui Provincial Hospital, Hefei, China. 4. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, 230032, Hefei, Anhui, China. panhaifeng1982@sina.com. 5. Anhui Provincial Laboratory of Population Health & Major Disease Screening and Diagnosis, Hefei, Anhui, China. panhaifeng1982@sina.com.
Abstract
OBJECTIVE: This study aims to investigate the plasma melatonin levels in systemic lupus erythematosus (SLE) patients and its relationship with clinical and laboratory features. PATIENTS AND METHODS: A total of 90 patients with SLE (82 females, 8 males; mean age 37.86 ± 13.98 years, range 19-77 years) and 90 healthy controls (82 females, 8 male; mean age 36.54 ± 10.89 years, range 22-60 years) were recruited for the current study. Plasma melatonin levels were detected by enzyme-linked immunosorbent assay. RESULTS: Melatonin levels were not significantly different in the plasma of patients with SLE compared with controls (P = 0.026). There was no significant difference regarding plasma melatonin level between SLE patients with nephritis and those without nephritis (P = 0.714); no significant difference was found between less active SLE and more active SLE (P = 0.791). The presence of IgM was associated with melatonin levels (P = 0.031) in SLE patients. CONCLUSIONS: There is no significant difference in plasma melatonin levels between SLE patients and controls. Further studies are needed to elucidate the role of melatonin in SLE.
OBJECTIVE: This study aims to investigate the plasma melatonin levels in systemic lupus erythematosus (SLE) patients and its relationship with clinical and laboratory features. PATIENTS AND METHODS: A total of 90 patients with SLE (82 females, 8 males; mean age 37.86 ± 13.98 years, range 19-77 years) and 90 healthy controls (82 females, 8 male; mean age 36.54 ± 10.89 years, range 22-60 years) were recruited for the current study. Plasma melatonin levels were detected by enzyme-linked immunosorbent assay. RESULTS:Melatonin levels were not significantly different in the plasma of patients with SLE compared with controls (P = 0.026). There was no significant difference regarding plasma melatonin level between SLEpatients with nephritis and those without nephritis (P = 0.714); no significant difference was found between less active SLE and more active SLE (P = 0.791). The presence of IgM was associated with melatonin levels (P = 0.031) in SLEpatients. CONCLUSIONS: There is no significant difference in plasma melatonin levels between SLEpatients and controls. Further studies are needed to elucidate the role of melatonin in SLE.
Authors: D Pozo; M Delgado; J M Fernandez-Santos; J R Calvo; R P Gomariz; I Martin-Lacave; G G Ortiz; J M Guerrero Journal: FASEB J Date: 1997-05 Impact factor: 5.191
Authors: Pablo Medrano-Campillo; Helia Sarmiento-Soto; Nuria Álvarez-Sánchez; Ana I Álvarez-Ríos; Juan M Guerrero; Ismael Rodríguez-Prieto; María Jesús Castillo-Palma; Patricia J Lardone; Antonio Carrillo-Vico Journal: J Pineal Res Date: 2015-02-04 Impact factor: 13.007